AVEO Pharmaceuticals (AVEO) Tops Q3 EPS by 23c, Offers Gudiance

AVEO Pharmaceuticals (NASDAQ: AVEO) reported Q3 EPS of $0.14, $0.23 better than the analyst estimate of ($0.09).

Updated Financial Guidance

AVEO believes that its cash resources would allow the Company to fund current operations through the fourth quarter of 2017. This estimate does not include payment of potential licensing milestones or the costs of conducting any contemplated clinical trials and assumes no milestone payments from the Company’s partners, additional funding from new partnership agreements, equity financings, debt financings or accelerated repayment thereof or further sales of equity under the Company’s ATM. In addition, AVEO cannot estimate the impact on its cash resources of a settlement of claims with the SEC. The timing and nature of activities contemplated for 2015 and thereafter will be conducted subject to the availability of sufficient financial resources.

For earnings history and earnings-related data on AVEO Pharmaceuticals (AVEO) click here.

You May Also Be Interested In

• EMA validates Pfizer and Valneva's Lyme disease vaccine application
• Zentalis Pharmaceuticals prices $80.5M public stock offering
• Valvoline prices $600M senior notes offering, upsized from $500M